Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320155 | 1.00 | NOS1 (0.46) | NOS1NOS3NOS2SLC7A5CA1 | |
| SCHEMBL919727 | 1.00 | NOS1 (0.46) | NOS1NOS3NOS2SLC7A5CA1 | |
| Hydrochloric Acid SCHEMBL919725 | 0.98 | NOS1 (0.45) | NOS1NOS3NOS2SLC7A5CA1 | |
| Hydrochloric Acid SCHEMBL146833 | 0.98 | NOS1 (0.45) | NOS1NOS3NOS2SLC7A5CA1 | |
| Hydrochloric Acid SCHEMBL146832 | 0.98 | NOS1 (0.45) | NOS1NOS3NOS2SLC7A5CA1 | |
| Trifluoroacetic Acid SCHEMBL28911781 | 0.88 | NOS1 (0.40) | NOS1NOS3NOS2SLC7A5CA1 | |
| Trifluoroacetic Acid SCHEMBL28911780 | 0.88 | NOS1 (0.40) | NOS1NOS3NOS2SLC7A5CA1 | |
| SCHEMBL28062530 | 0.87 | NOS1 (0.46) | NOS1NOS3NOS2SLC7A5CA1 | |
| SCHEMBL6565617 | 0.86 | NOS1 (0.46) | NOS1NOS3NOS2SLC7A5CA1 | |
| SCHEMBL31107708 | 0.86 | NOS1 (0.46) | NOS1NOS3NOS2SLC7A5CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1052 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119470406-A | Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof | 山东新华莎罗雅生物技术有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119241385-A | Beta-acyloxy enamide derivative and preparation method and application thereof | 江西师范大学 | 2025-01-03 | — | — | CN | claimed |
| CN-118239879-A | Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine | 泰山学院 | 2024-06-25 | — | — | CN | claimed |
| CN-109928908-B | Preparation method and intermediate of drug-linker MC-MMAF for antibody drug conjugate | 联宁（苏州）生物制药有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-110269858-B | Twin medicine for treating ischemic stroke and preparation method thereof | 贵州医科大学 | 2021-07-09 | — | — | CN | claimed |
| CN-110269858-A | It is a kind of to treat twin medicine of cerebral arterial thrombosis and preparation method thereof | 贵州医科大学 | 2019-09-24 | — | — | CN | claimed |
| JP-61282337-A | — | — | None | — | — | JP | disclosed |
| JP-59163347-A | — | — | None | — | — | JP | disclosed |
| CN-122070146-A | Antibody coupling medicine, preparation method and application thereof | 杭州爱科瑞思生物医药有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026098684-A1 | HETEROCYCLIC COMPOUND AS KRAS INHIBITOR, PREPARATION THEREFOR AND THERAPEUTIC USE THEREOF | 上海科州药物股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4733307-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| JP-S61282337-A | PRODUCTION OF OPTICALLY ACTIVE BETA-SUBSTITUTED DELTAKETOCARBOXYLIC ACID OR ESTER THEREOF | KURARAY CO LTD | 1986-12-12 | — | — | JP | disclosed |
| US-4526896-A | Microbiocides | RIKER LABORATORIES, INC. (US) | 1985-07-02 | — | — | US | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
| JP-S59163347-A | PREPARATION OF OPTICALLY ACTIVE ALPHA,ALPHA-DISUBSTITUTED-BETA- KETOESTER | KURARAY CO LTD | 1984-09-14 | — | — | JP | disclosed |
| US-4237046-A | VASODILATION | BOARD OF REGENTS THE, THE UNIVERSITY OF TEXAS SYSTEM | 1980-12-02 | — | — | US | disclosed |
| US-4122090-A | Cyclic esters of 3,4-dihydroxy-thiophene-1,1-dioxide compounds and 3,4-dihydroxy-cyclopentadienone compounds | BASF AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
| US-4111933-A | PROTECTION OF FUNCTIONAL GROUPS DURING REACTION AND THEIR SUBSEQUENT RESTORATION | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | NOS1 3798/4885NOS3 3975/4885NOS2 4518/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | NOS1 828/4885NOS3 1235/4885NOS2 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.